Aclaris Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $197.3M | $27.3M |
| FY2022 | — | $197.6M | $45.3M |
| FY2023 | — | $157.2M | $39.9M |
| FY2024 | — | $155.6M | $24.6M |
| FY2025 | — | $103.1M | $20.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $197.3M | $27.3M |
| FY2022 | — | $197.6M | $45.3M |
| FY2023 | — | $157.2M | $39.9M |
| FY2024 | — | $155.6M | $24.6M |
| FY2025 | — | $103.1M | $20.0M |